ArticleLasers in medical science2026
Systematic photodynamic therapy for concurrent cervical-vaginal high-grade squamous intraepithelial lesion: a series of eight cases.
Article in Lasers in medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Concurrent cervical-vaginal high-grade squamous intraepithelial lesion (HSIL) is increasingly prevalent with carcinogenic potential. For gynecologic oncologists, non-invasive, organ-preserving treatment of this condition remains a challenge. While Hiporfin-photodynamic therapy (PDT) has proven effective for cervical HSIL or vaginal HSIL alone, its efficacy in concurrent cervical-vaginal HSIL remains unreported. We treated 8 pathologically confirmed patients with Hiporfin-PDT: 2.0 mg/kg intravenous Hiporfin followed by 630-nm red laser irradiation 48-72 h later, with one session per patient initially. At 3-6 months, the complete response (CR) rate was 75.0% (6/8); the 2 partial response (PR) patients achieved CR after a second PDT session or two sessions of thermocoagulation. Our preliminary findings suggest that Hiporfin-PDT has potential feasibility as a non-invasive option for concurrent cervical-vaginal HSIL, warranting further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.